Revance Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • March 5th, 2024 • Revance Therapeutics, Inc. • Pharmaceutical preparations
Revance Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 16,000,000 shares (the “Securities”) of common stock, $0.001 par value per share (“Stock”) of the Company. To the extent there are no additional Underwriters listed on Schedule I other than you, the term “Representative” as used herein shall mean you, as the Underwriters, and the term “Underwriters” shall mean either the singular or plural as the context requires.
